Recently, Chengdu Kanghua Biological Products Company Limited ("Kanghua Biological" or the "Company") signed an Exclusive License Agreement with HilleVax.INC ("HilleVax"). INC ("HilleVax"). Kanghua Biologicals licensed HilleVax to develop, manufacture and commercialize Recombinant Hexavalent Norovirus Vaccine and its derivatives in areas other than China (including Hong Kong, Macao and Taiwan).

Kanghua Biologicals will receive an initial payment of US$15 million for this transaction and is expected to receive milestone payments of US$255.5 million upon the achievement of certain development and sales milestones, and Kanghua Biologicals is also entitled to a single-digit percentage sales commission on net sales in territories other than China (including Hong Kong, Macao and Taiwan).

Using genetic engineering technology, Kanghua Biologicals has constructed a recombinant hexavalent norovirus vaccine based on Virus-Like Particles (VLPs), which encompasses the six major prevalent genotypes of norovirus, and theoretically protects against more than 90% of norovirus infections and acute gastroenteritis caused by norovirus, and is now licensed for clinical studies in Australia and the United States. To date, the recombinant hexavalent norovirus vaccine is the first and only clinically licensed hexavalent norovirus vaccine in the world. As part of the exclusive license agreement, Kanghua will provide the recombinant hexavalent norovirus vaccine (HilleVax product code HIL-216) to HilleVax for use in a near-term clinical trial, which is scheduled to begin in 2024.

Kanghua Biologicals will receive an initial payment of $15.0 million in this transaction and is expected to receive milestone payments of $255.5 million upon the achievement of certain development and sales milestones, and is also entitled to a single-digit percentage sales commission on net sales outside of China (including Hong Kong, Macao and Taiwan).

Using genetic engineering technology, Kanghua Biologicals has constructed a recombinant hexavalent norovirus vaccine based on Virus-Like Particles (VLPs), which encompasses the six major prevalent genotypes of norovirus, and theoretically protects against more than 90% of norovirus infections and acute gastroenteritis caused by norovirus, and is now licensed for clinical studies in Australia and the United States. To date, the recombinant hexavalent norovirus vaccine is the first and only clinically licensed hexavalent norovirus vaccine in the world. As part of the exclusive license agreement, Kanghua will provide the recombinant hexavalent norovirus vaccine (HilleVax product code HIL-216) to HilleVax for use in a near-term clinical trial, which is scheduled to commence in 2024.

https://mp.weixin.qq.com/s/gANX1-ApQgSp_OzjW5OT5A